Table 2.
Agreement between QFT-GIT and TST, stratified by BCG vaccination status
| QFT-GIT, n (%) | ||||
| TST >5 mm | Positive | Negative | Agreement | |
| All subjects | Positive | 7 (4.9) | 33 (23.1) | Raw = 72.7% |
| Negative | 6 (4.2) | 97 (67.8) | κ = 0.15 | |
| BCG vaccinated | Positive | 3 (4.1) | 22 (30.1) | Raw = 64.4% |
| Negative | 4 (5.5) | 44 (60.3) | κ = 0.04 | |
| No BCG | Positive | 3 (5.4) | 7 (12.5) | Raw = 85.8% |
| Negative | 1 (1.8) | 45 (80.4) | κ = 0.36 | |
| TST >10 mm | Positive | Negative | Agreement | |
| All subjects | Positive | 7 (4.9) | 22 (15.4) | Raw = 79.7% |
| Negative | 6 (4.2) | 108 (75.5) | κ = 0.19 | |
| BCG vaccinated | Positive | 3 (4.1) | 15 (20.5) | Raw = 74.0% |
| Negative | 4 (5.5) | 51 (69.9) | κ = 0.12 | |
| No BCG | Positive | 2 (3.6) | 3 (5.4) | Raw = 91.1% |
| Negative | 2 (3.6) | 49 (87.5) | κ = 0.40 | |
Kappa (κ) values with statistically significant p values are printed bold. P values for TST >5 mm: All subjects, p = 0.048; BCG vaccinated, p = 0.69; no BCG, p = 0.016. P values for TST >10 mm: All subjects, p = 0.021; BCG vaccinated, p = 0.35; No BCG, p = 0.036. BCG = Bacillus Calmette-Guérin; QFT-GIT = QuantiFERON®-TB Gold in Tube; TST = tuberculin skin test.